Photo by ricochet64/Shutterstock.com
The U.S. Court of Appeals for the Federal Circuit has just made it more difficult to sue generic drug makers for patent infringement in Delaware and New Jersey.
Thursday's ruling means fewer pharmaceuticals may bring Hatch-Waxman Act lawsuits in the popular venues of Delaware and New Jersey.
November 05, 2020 at 06:21 PM
1 minute read
The original version of this story was published on National Law Journal
Photo by ricochet64/Shutterstock.com
The U.S. Court of Appeals for the Federal Circuit has just made it more difficult to sue generic drug makers for patent infringement in Delaware and New Jersey.
Presented by BigVoodoo
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Truly exceptional Bergen County New Jersey Law Firm is growing and seeks strong plaintiff's personal injury Attorney with 5-7 years plaintif...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS